Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Invasive Fungal Infections Market Size Changed, over the years?

In the past few years, there has been a steady increase in the market size for invasive fungal infections. It is expected to extend from $7.58 billion in 2024 to $7.96 billion in 2025, witnessing a compound annual growth rate (CAGR) of 5.0%. Factors such as the worldwide proliferation of infections, hematopoietic stem cell transplants, an aging global demographic, hospital-acquired infections, and environmental considerations can justify the growth during the historic phase.

How Much Will the Invasive Fungal Infections Market Be Worth in 2029?

In the ensuing years, the market size for invasive fungal infections is anticipated to witness consistent expansion, rising to $9.6 billion by 2029 with a compound annual growth rate (CAGR) of 4.8%. The market’s growth during the forecast period can be credited to factors such as preparedness on a global health scale, public health literacy, new antifungal treatments, the effects of climate change, and multi-faceted methods. Key trends forecasting this period include advancements in diagnostic technologies, tailored treatment strategies, a focus on patient-centered care, dual antifungal therapies, and collaborative efforts in drug development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp

Which is the Largest Company in the Invasive Fungal Infections Market?

Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK PLC, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMérieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd., F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

What Are the Main Market Drivers in the Invasive Fungal Infections Industry?

As the number of people affected by human immunodeficiency virus (HIV) increases, so too does the invasive fungal infection market’s potential for expansion. The deficiency in the immune system’s capabilities to ward off diseases and ailments, brought on by HIV or acquired immunodeficiency syndrome (AIDS), escalates the probability of developing invasive fungal infections. This subsequently provides manufacturers with opportunities to innovate and deliver more potent antifungal pharmaceuticals. Statistics from The Joint United Nations Programme on HIV/AIDS (UNAIDS) indicate that in July 2023, HIV’s global prevalence escalated to 39 million in 2022, marking a 3.17% leap from 37.7 million in 2020. Alongside this, roughly 1.3 million new HIV cases were reported in 2022. Such an upswing in HIV-affected population will act as a catalyst for advancing the invasive fungal infection market. Simultaneously, a surge in the pool of cancer patients is projected to propel the invasive fungal infections market forward. The term “cancer patent” denotes patents linked with breakthroughs, innovations, or technologies concerning cancer’s diagnosis, treatment, or prevention. Particularly, cancer patients, especially those with vulnerable immune systems, are often at risk of invasive fungal infections (IFIs), which can pose serious health risks. As per the data from the National Cancer Institute in the U.S, the number of cancer survivors is estimated to hit 26.0 million by 2040. Moreover, those who survive more than five years following their cancer diagnosis are set to increase nearly 30%, reaching 16.3 million over the next decade. Hence, the upward trajectory of the cancer patient population is steering the growth of the invasive fungal infections market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13189&type=smp

How Is the Invasive Fungal Infections Market Segments Structured?

The invasive fungal infections market covered in this report is segmented –

1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Type

2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Type

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis

2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation

3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis

4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis

5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis

6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections

What Strategic Trends Are Transforming the Invasive Fungal Infections Market?

Leading businesses in the invasive fungal infection market are concentrating their efforts on the development of innovative products, an example of which is Zisavel capsules. These capsules promise to enhance treatment effectiveness, better patient results, and broaden accessibility for individuals impacted by serious fungal infections. Zisavel capsules, which are generic antifungal medicines formulated from isavuconazole, are used to combat invasive aspergillosis and mucormycosis. These 100 mg capsules seek to offer a budget-friendly alternative for patients and increase their access to effective therapy. For example, in October 2023, an India-based generic and specialty pharmaceutical company, BDR Pharmaceuticals, unveiled a generic antifungal medicine, Zisavel Capsules, that target invasive aspergillosis and mucormycosis. Zisavel is prescribed for treating severe and potentially life-threatening fungal infections such as invasive aspergillosis and mucormycosis. By introducing Zisavel, the goal is to make treatment more affordable for patients by drastically cutting costs in comparison to existing options like voriconazole and posaconazole.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Which Global Regions Offer the Highest Growth in the Invasive Fungal Infections Market?

North America was the largest region in the invasive fungal infections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13189

This Report Delivers Insight On:

1. How big is the invasive fungal infections market, and how is it changing globally?

2. Who are the major companies in the invasive fungal infections market, and how are they performing?

3. What are the key opportunities and risks in the invasive fungal infections market right now?

4. Which products or customer segments are growing the most in the invasive fungal infections market?

5. What factors are helping or slowing down the growth of the invasive fungal infections market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model